Search Results

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. today announced its first quarter 2022 financial results and provided a business update.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. , a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the presentation of additional safety and efficacy data from the Company’s pivotal Phase 3 ATTACK trial.

Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics’ available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.

Entasis Therapeutics Holdings Inc. today announced full year 2021 financial results and provided a business update.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Entasis Therapeutics Holdings Inc. today announced that its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. (“Innoviva”) to acquire all of the outstanding equity securities of Entasis that are not currently owned by Innoviva for a per share consideration of $1.80 payable in cash.

Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.